| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 11/14/2013 | US20130302317 Siglec-9 Binding Agents |
| 11/14/2013 | US20130302316 Antagonist antibody for the treatment of cancer |
| 11/14/2013 | US20130302315 Optimized Fc Variants |
| 11/14/2013 | US20130302314 Anti-c epsilon mx antibodies capable of binding to human mige on b lymphocytes |
| 11/14/2013 | US20130302312 Method of treating a pathological syndrome and a pharmaceutical agent |
| 11/14/2013 | US20130302250 Single domain binding molecule |
| 11/13/2013 | EP2662449A2 Immunoglobulin fusion proteins |
| 11/13/2013 | EP2662390A1 Interferon alpha receptor 1 antibodies and their uses |
| 11/13/2013 | EP2662389A1 Method for preparing antigen to obtain antihydrophobic peptide antibody |
| 11/13/2013 | EP2662388A1 Recombinant antibodies to the vascular endothelial growth factor (vegf) which are obtained by means of mutagenesis of variable regions |
| 11/13/2013 | EP2662387A1 Antibody to signal peptide of amyloid precursor protein |
| 11/13/2013 | EP2662386A1 Antibodies that bind to PLAC1 and block interaction between PLAC1 and FGF7 |
| 11/13/2013 | EP2662385A1 Method for improving physical properties of antibody |
| 11/13/2013 | EP2662091A2 Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases |
| 11/13/2013 | EP2661500A2 Clostridium difficile antigens |
| 11/13/2013 | EP2661450A1 Plasma kallikrein binding proteins |
| 11/13/2013 | EP2661449A1 Ligands that bind tgf-beta receptor ii |
| 11/13/2013 | EP2661448A2 Anti-il-12/il-23 antibodies and uses thereof |
| 11/13/2013 | EP2661447A1 Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors |
| 11/13/2013 | EP2661446A1 Alphabody libraries and methods for producing the same |
| 11/13/2013 | EP2661445A2 Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease |
| 11/13/2013 | EP2661444A1 Alphabodies specifically binding to class-i viral fusion proteins and methods for producing the same |
| 11/13/2013 | EP2661443A1 Alphabodies specifically binding to viral proteins and methods for producing the same |
| 11/13/2013 | CN103391946A Anti-il28b antibody and method for assaying il28b using same |
| 11/13/2013 | CN103388013A Method for preparing homodimer protein mixture by virtue of charge repulsion |
| 11/13/2013 | CN103387997A Pelodiscus sinensis picornavirus complete genome sequence and applications thereof |
| 11/13/2013 | CN103387971A Recombinant human pepsinogen II isozyme chimeric protein, and preparation method and applications thereof |
| 11/13/2013 | CN103387611A Antibody, method and kit used for detecting and determining glycyrrhizic acid |
| 11/13/2013 | CN103387605A RTN4B polypeptide and monoclonal antibody thereof, hybridoma cell strain generating monoclonal antibody, and preparation and application of RTN4B polypeptide, monoclonal antibody and hybridoma cell strain |
| 11/13/2013 | CN103387532A Preparation method of anti-aristololactam FI and aristolochic acid IVa monoclonal antibody, and application of monoclonal antibody |
| 11/13/2013 | CN102464726B Epimedium polysaccharide and components thereof as well as application thereof to vaccine adjuvant |
| 11/13/2013 | CN102241741B Prion protein ligands and methods of use |
| 11/13/2013 | CN102099057B A conjugate of an antibody against CD4 and antifusogenic peptides |
| 11/13/2013 | CN102070710B Specific GRA2a (Glycine Rich Antigen)-type antigenic protein of clonorchis sinensis and application thereof |
| 11/13/2013 | CN101981053B Pegylated Abeta FAB |
| 11/13/2013 | CN101957377B Method for preparing fluorescent antibody for detecting avian influenza virus and solid phase immunofluorescence detection kit |
| 11/13/2013 | CN101889025B Antibody purification by cation exchange chromatography |
| 11/13/2013 | CN101868478B Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof |
| 11/13/2013 | CN101802010B Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| 11/13/2013 | CN101687929B Monoclonal antibodies against claudin-18 for treatment of cancer |
| 11/13/2013 | CN101679516B Antigen-binding proteins targeting s. aureus ORF0657 |
| 11/13/2013 | CN101606062B Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy |
| 11/13/2013 | CN101605815B Method and arrangement for allowing enterprise and personal domains in the ims |
| 11/13/2013 | CN101548034B Design and construction of diverse synthetic peptide and polypeptide libraries |
| 11/13/2013 | CN101287764B Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| 11/13/2013 | CN101151277B Anti-interferon gamma antibodies and methods of use thereof |
| 11/12/2013 | US8580933 Variable tangential flow filtration |
| 11/12/2013 | US8580932 Method of thermostabilization of a protein and/or stabilization towards organic solvents |
| 11/12/2013 | US8580930 Hepatocyte growth factor (HGF) binding proteins |
| 11/12/2013 | US8580929 DNA sequence encoding a retinoic acid regulated protein |
| 11/12/2013 | US8580928 CDR-repaired antibodies |
| 11/12/2013 | US8580927 Engineered antibody constant domain molecules |
| 11/12/2013 | US8580926 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan |
| 11/12/2013 | US8580925 Method for examining carcinoma and adenoma |
| 11/12/2013 | US8580923 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 11/12/2013 | US8580921 Protein nanorings |
| 11/12/2013 | US8580920 Peptides useful for skin lightening |
| 11/12/2013 | US8580918 Peptidic GLP-2 agonists |
| 11/12/2013 | US8580744 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms |
| 11/12/2013 | US8580312 Radiation therapy agent |
| 11/12/2013 | US8580262 Group B Streptococcus antigens |
| 11/12/2013 | US8580261 Methods for prevention and treatment of inflammation using anti-chemokine antibodies |
| 11/12/2013 | US8580260 Method of using anti-IL-13 antibodies |
| 11/12/2013 | US8580254 Anti-IGF antibodies |
| 11/12/2013 | CA2714357C Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 11/12/2013 | CA2611924C Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection |
| 11/12/2013 | CA2549652C Cd40 antibody formulation and methods |
| 11/12/2013 | CA2532173C Antibodies against insulin-like growth factor i receptor and uses thereof |
| 11/12/2013 | CA2522331C Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| 11/12/2013 | CA2515474C Antibody molecules having specificity for human il-1.beta. |
| 11/12/2013 | CA2477012C Anti-a.beta. antibodies and their use |
| 11/12/2013 | CA2471924C Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death |
| 11/12/2013 | CA2342376C A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 11/07/2013 | WO2013166500A1 Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| 11/07/2013 | WO2013166448A1 Stable formulations containing anti-pcsk9 antibodies |
| 11/07/2013 | WO2013166236A1 Human antibodies to fel d1 and methods of use thereof |
| 11/07/2013 | WO2013166011A2 Binding proteins having tethered light chains |
| 11/07/2013 | WO2013165940A1 Anti-pmel17 antibodies and immunoconjugates |
| 11/07/2013 | WO2013165894A2 St2l antagonists and methods of use |
| 11/07/2013 | WO2013165791A1 Anti-il-23p19 antibodies |
| 11/07/2013 | WO2013165690A1 Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| 11/07/2013 | WO2013165593A1 COMPOSITIONS AND METHODS FOR β-GLUCAN IMMUNOTHERAPY |
| 11/07/2013 | WO2013165591A1 β-GLUCAN IMMUNOTHERAPEUTIC METHODS |
| 11/07/2013 | WO2013165590A1 Methods for treating idiopathic pulmonary fibrosis |
| 11/07/2013 | WO2013164837A1 Pharmaceutical formulations of tnf-alpha antibodies |
| 11/07/2013 | WO2013164789A2 Antibody formulatoin |
| 11/07/2013 | WO2013164694A1 Targeted/immunomodulatory fusion proteins and methods for making same |
| 11/07/2013 | WO2013164689A2 Humanized pan-her antibody compositions |
| 11/07/2013 | WO2013164444A1 Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| 11/07/2013 | WO2013164440A1 Methods related to treatment of inflammatory diseases and disorders |
| 11/07/2013 | WO2013164325A1 Multispecific antigen binding proteins |
| 11/07/2013 | WO2013164290A2 Antibodies or fragments thereof for use in the treatment of ocular diseases |
| 11/07/2013 | WO2013138702A3 Methods for predicting gastrointestinal immune - related adverse events (gi-irae) in patients treated with co - stimulatory pathway modulators |
| 11/07/2013 | WO2013138680A4 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| 11/07/2013 | WO2013135602A3 Combination therapy for the treatment of ovarian cancer |
| 11/07/2013 | WO2013120012A3 Cdim binding proteins and uses thereof |
| 11/07/2013 | WO2013114112A3 Stabilized aqueous antibody compositions |
| 11/07/2013 | WO2013109974A3 Anti-cxcr3 antibodies |
| 11/07/2013 | WO2013089877A3 Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs |
| 11/07/2013 | WO2012145507A3 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |